RIVASTIGMINE TARTRATE
Rivastigmine tartrate is an acetylcholinesterase inhibitor indicated for the treatment of mild-to-moderate dementia. It is specifically approved for patients with dementia of the Alzheimer’s type or dementia associated with Parkinson’s disease. The medication is intended to manage symptoms of these conditions, though it does not alter the course of the underlying dementing process.
How RIVASTIGMINE TARTRATE Works
Rivastigmine tartrate is thought to exert its therapeutic effect by enhancing cholinergic function. It achieves this by increasing the concentration of acetylcholine through the reversible inhibition of its hydrolysis by the enzyme cholinesterase. Because the drug works by maintaining available acetylcholine, its clinical effect may diminish as the disease advances and fewer cholinergic neurons remain functionally intact.
Details
- Status
- Prescription
- First Approved
- 2007-10-22
- Routes
- ORAL
- Dosage Forms
- CAPSULE
Companies
RIVASTIGMINE TARTRATE Approval History
What RIVASTIGMINE TARTRATE Treats
2 indicationsRIVASTIGMINE TARTRATE is approved for 2 conditions since its original approval in 2007. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Mild-to-moderate dementia of the Alzheimer’s type
- Mild-to-moderate dementia associated with Parkinson’s disease
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
RIVASTIGMINE TARTRATE FDA Label Details
ProIndications & Usage
Rivastigmine tartrate capsules are an acetylcholinesterase inhibitor indicated for treatment of: Mild-to-moderate dementia of the Alzheimer’s type (AD) Mild-to-moderate dementia associated with Parkinson’s disease (PD) 1.1 Alzheimer’s Disease Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type (AD). 1.2 Parkinson’s Disease Dementia Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PD).
Want competitive intelligence?
See who's developing similar drugs and track their progress
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.